Typically, the pharmaceutical industry operates within a legal-moral ... from $816m per drug in 2010 to $394m now. Price-gouging scandals are only likely to intensify this trend: around the ...

Kobayashi Pharmaceutical Co ... citing a difficulty in assessing the impact of the scandal. The report compiled by an investigative committee consisting of lawyers listed a number of crisis ...

The temporary shutdowns of scandal-hit pharmaceutical companies have led to a shortage of more than 3,000 drugs, mostly generic medications, prompting the health ministry to instruct the industry ...

The Chinese bribery scandal is starting to hurt big pharma ... Ed Silverman is a prize-winning journalist who has covered the pharmaceutical industry for the past 16 years. In addition to editing ...

I write about business model strategy and execution across healthcare. The pharmaceutical industry has long anticipated the dreaded day that finally arrived last week. The Department of Health and ...

Six pharmaceutical executives agreed to settlements and are cooperating to back Maryland’s claims in three cases. “The ...

A look back at some of this week's most eyecatching stories, including the scandal around ... Report reviews big pharma's social media activity A new review of the pharma industry’s social ...

OSAKA -- Activist investor Oasis Management has requested that Kobayashi Pharmaceutical hold an extraordinary shareholders meeting in response to the scandal surrounding a red yeast supplement ...